30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q14 Revenue: CONMED

$92.8MM, -3%

  • U.S. SportsMed -9% due to reduced procedure-specific and resection sales, plus previous discontinuation of PRP products
  • U.S. Powered Instruments +1% (Capital handpieces +6%, Single-use burrs and blades -3%)
  • Edge ablation bipolar radiofrequency arthroscopic energy system now slated for early 2015
  • Capital market is clearly improving vs 1H